Clinical trials: Squamous Oesophageal Cancer, active
Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab
Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
At present, concurrent chemoradiotherapy (cCRT) with platin-based dual-drug regimen is the standard treatment for inoperable, locally advanced esophageal cancer in patients with a good performance status.
- Conditions
- Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab, Radiotherapy, Concurrent Chemoradiotherapy
- Trial name
- NCT06342167
- Testing
- Radiotherapy, Programmed Cell Death Protein 1 Inhibitor, Immunonutrition support
- Where
- 10 sites in China
- Volunteers
- 57 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Advanced Cancer, Advanced Malignancies
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
- Conditions
- Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer
- Trial name
- ARC-25 (NCT05891171)
- Testing
- AB598, Zimberelimab, Fluorouracil
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 40 people
- Sponsor
- Arcus Biosciences, Inc.
Esophageal Squamous Cell Carcinoma
PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC
This is a phase 2/window of opportunity study to determine the efficacy, by clinical complete response, and safety of induction toripalimab (PD-1 inhibitor) followed by definitive chemoradiotherapy (dCRT) and adjuvant toripalimab…
- Trial name
- NCT07836049
- Testing
- Toripalimab, Carboplatin + Paclitaxel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Esophageal Squamous Cell Carcinoma
A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.
This is a multicenter phase 2/3 clinical study to evaluate the efficacy and safety of SYS6010 plus SG001±5-FU/Capecitabine as first-line treatment, in patients with advanced/metastatic esophageal squamous cell carcinoma.
- Trial name
- NCT07251062
- Testing
- SYS6010+SG001+ physician's choice (Capecitabine or 5-FU), Investigator's choice of SOC, SYS6010+SG001
- Volunteers
- 737 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Esophageal Squamous Cell Carcinoma, Immunotherapy
Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
To evaluate the efficacy and safety of adebrelimab with or without induction chemotherapy followed by concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma, Immunotherapy, Biomarkers
- Trial name
- RICE (NCT06510660)
- Testing
- adebrelimab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Fujian Medical University Union Hospital
Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms
- Trial name
- NCT05208762
- Testing
- PF-08046054, pembrolizumab
- Where
- 62 sites in United States, Belgium and 9 more
- Volunteers
- 714 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Oral Cavity Cancer, Dysphagia
Dysphagia and Quality of Life in Patients With Oral Squamous Cell Carcinoma Before and After Treatment
While the group of oral cavity cancer (OCC) survivors continue to increase, surgeons and oncologist intensify their search for improved treatment and rehabilitation methods to reduce the morbidity of management without…
- Conditions
- Oral Cavity Cancer, Dysphagia, Quality of Life
- Trial name
- NCT06407570
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- University of Aarhus
Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
Registry Platform Gastric/Esophageal Cancer (SAPHIR)
The registry aims to collect and analyse information on the antineoplastic treatment of patients with metastatic esophageal, gastric or gastroesophageal junction cancer, treated in palliative intention in daily routine practice…
- Conditions
- Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- SAPHIR (NCT04290806)
- Testing
- Routine care as per site standard
- Where
- Germany
- Volunteers
- 1,900 people
- Sponsor
- iOMEDICO AG
Esophagus Cancer
A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to learn if Afatinib plus Palbociclib works in previously treated recurrent or metastatic esophageal squamous cell carcinoma.
- Trial name
- NCT06753747
- Testing
- Palbociclib, Afatinib(30mg), Afatinib(40mg)
- Where
- China
- Volunteers
- 45 people
- Sponsor
- West China Hospital
Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III
Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)
The goal of this clinical trial is to assess the 1-year DFS rate of toripalimab adjuvant therapy in participants with resected esophageal squamous cell carcinoma (ESCC) who achieved pCR.
- Trial name
- NCT06903871
- Testing
- TORIPALIMAB INJECTION(JS001 )
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Hebei Medical University Fourth Hospital
Esophageal Squamous Cell Carcinoma
Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study
This is a domestic exploratory, single-arm clinical study enrolling patients with histologically or cytologically confirmed locally advanced esophageal squamous cell carcinoma (ESCC), aiming to evaluate the efficacy and safety of…
- Trial name
- NCT07437898
- Testing
- Adebrelimab, chemotherapy
- Where
- China
- Volunteers
- 42 people
- Sponsor
- The Affiliated Hospital of Putian University
Esophageal Squamous Cell Carcinoma (ESCC)
Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
This study aims to systematically evaluate the safety and efficacy of adalimumab combined with paclitaxel, carboplatin, and short-course radiotherapy in the neoadjuvant treatment of esophageal squamous cell carcinoma.
- Trial name
- ANCRE (NCT07595770)
- Testing
- • Adebrelimab and nab-paclitaxel, carboplatin in Combination With radiotherapy
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Esophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Esophageal Cancer
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
SCR-ESCC-02 is a multicenter, phase I/II clinical study to investigate the safety and efficacy of induction immunochemotherapy followed by concurrent chemoradiotherapy with anti-PD-1 therapy in patients diagnosed with locally…
- Trial name
- NCT06173986
- Testing
- PD-1inhibitor, nab-paclitaxel + cisplatin, Radiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Chest Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC
This multicenter, prospective Phase II study investigates a response-adapted organ-preservation strategy in patients with resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- SCOPE (NCT07711470)
- Testing
- Sugemalimab and Chemotherapy, Nab-paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Resectable Esophageal Squamous Cell Carcinoma
Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer
Evaluating the efficacy and safety of PD-L1 (Programmed Death-L1)antibody combined with endoscopy and radiotherapy for inoperable cT1b-2 (clinical stage tumor 1b-2) esophageal squamous cell carcinoma
- Trial name
- NCT06599775
- Testing
- Adebrelimab injection, Albumin-Bound Paclitaxel, Carboplatin injection
- Volunteers
- 42 people
- Sponsor
- Shanghai Zhongshan Hospital
Carcinoma, Squamous Cell, Oral Cancer
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
Participants in this study have a type of cancer called squamous cell carcinoma of the head and neck (SCCHN). Their SCCHN has spread around the area where the cancer first started. This is called locally-advanced SCCHN.
- Conditions
- Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer, Larynx Cancer
- Trial name
- NCT03174275
- Testing
- Durvalumab, Carboplatin, Nab-paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Esophageal Cancer
Tpex Subsets in Negative Tumor Draining Lymph Nodes for Predicting the Efficacy of PD 1 Inhibitors in Advanced or Recurrent Esophageal Squamous Cell Carcinoma
The goal of this observational study is to to determine whether patients with a high proportion of precursor exhausted T cells (Tpex) in negative tumor draining lymph nodes have longer overall survival.
- Trial name
- NCT07533357
- Volunteers
- 158 people
- Sponsor
- Fudan University
Esophageal Cancer, Sentinel Lymph Node
A Non-inferiority Study of Indocyanine Green-guided Sentinel Lymph Node Mapping Versus Conventional Lymph Node Dissection in Esophageal Cancer
In the comprehensive treatment system for esophageal cancer, surgical resection combined with regional lymph node dissection remains the core component for achieving cure in patients with resectable esophageal squamous cell…
- Conditions
- Esophageal Cancer, Sentinel Lymph Node, Lymphadenectomy, Indocyanine Green (ICG)
- Trial name
- SIGN (NCT07788001)
- Testing
- ICG-guided sentinel lymph node dissection, ICG-guided systematic lymph node dissection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fujian Medical University Union Hospital
Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC)
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
This is a multi-regional, multi center, open label, first in human (FIH), dose-escalation, and dose-expansion study of AP203 to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- APT-CUBE (NCT05473156)
- Testing
- AP203
- Where
- Taiwan
- Volunteers
- 168 people
- Sponsor
- AP Biosciences Inc.
Esophageal Squamous Cell Cancer
Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma
Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive malignant tumors. Although neoadjuvant chemoradiotherapy combined with surgery has significantly improved the survival rate of patients with locally advanced…
- Trial name
- NCT06596954
- Testing
- lymphocyte-sparing radiotherapy, conventional radiotherapy
- Where
- China
- Volunteers
- 212 people
- Sponsor
- Ruijin Hospital